The expression of p-CDK1, p-STAT3, CD44, and Sox2 was increased by gemcitabine, while fisetin could reverse the upregulation of these proteins in the combination therapy group, suggesting that inhibition of cancer stemness-related proteins by fisetin enhanced the effects of gemcitabine (Fig. 7f). The gene discussed is SOX2; the disease is cancer.